100 related articles for article (PubMed ID: 3876517)
1. Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome.
Tomizawa S; Maruyama K; Nagasawa N; Suzuki S; Kuroume T
Nephron; 1985; 41(2):157-60. PubMed ID: 3876517
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Nephron; 2001 Feb; 87(2):111-7. PubMed ID: 11244304
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Nephron; 2000 Jun; 85(2):127-33. PubMed ID: 10867518
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome.
Maruyama K; Tomizawa S; Seki Y; Arai H; Kuroume T
Nephron; 1992; 62(1):27-30. PubMed ID: 1436287
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15 and interleukin-12 have an additive effect on the release of vascular permeability factor by peripheral blood mononuclear cells in normals and in patients with nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Clin Nephrol; 1999 Jul; 52(1):10-8. PubMed ID: 10442490
[TBL] [Abstract][Full Text] [Related]
6. Vascular permeability increasing factor (VPF) in IgA nephropathy.
Bakker WW; Beukhof JR; van Luijk WH; van der Hem GK
Clin Nephrol; 1982 Oct; 18(4):165-7. PubMed ID: 7140031
[TBL] [Abstract][Full Text] [Related]
7. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome.
Matsumoto K; Ohi H; Kanmatsuse K
Nephron; 1999; 82(1):32-8. PubMed ID: 10224482
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis.
Matsumoto K; Ohi H; Kanmatsuse K
Nephron; 1998; 78(4):403-9. PubMed ID: 9578066
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
Matsumoto K; Ohi H; Kanmatsuse K
Am J Nephrol; 1999; 19(1):21-7. PubMed ID: 10085445
[TBL] [Abstract][Full Text] [Related]
10. Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF).
Kondo S; Yoshizawa N; Kusumi Y; Takeuchi A; Torikata C
Clin Nephrol; 1999 Nov; 52(5):278-84. PubMed ID: 10584990
[TBL] [Abstract][Full Text] [Related]
11. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome.
Heslan JM; Branellec AI; Pilatte Y; Lang P; Lagrue G
Clin Exp Immunol; 1991 Oct; 86(1):157-62. PubMed ID: 1914229
[TBL] [Abstract][Full Text] [Related]
12. Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Clin Nephrol; 2001 Apr; 55(4):269-74. PubMed ID: 11334311
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.
Matsumoto K
Nephron; 1997; 75(2):154-9. PubMed ID: 9041534
[TBL] [Abstract][Full Text] [Related]
14. FK 506 for vascular permeability factor production in minimal change nephrotic syndrome.
Maruyama K; Tomizawa S; Seki Y; Arai H; Ogawa T; Kuroume T
Nephron; 1994; 66(4):486-7. PubMed ID: 7517020
[No Abstract] [Full Text] [Related]
15. Increased IL-12 release by monocytes in nephrotic patients.
Matsumoto K; Kanmatsuse K
Clin Exp Immunol; 1999 Aug; 117(2):361-7. PubMed ID: 10444271
[TBL] [Abstract][Full Text] [Related]
16. Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome.
Yoshizawa N; Kusumi Y; Matsumoto K; Oshima S; Takeuchi A; Kawamura O; Kubota T; Kondo S; Niwa H
Nephron; 1989; 51(3):370-6. PubMed ID: 2918948
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis.
Matsumoto K; Ohi H; Kanmatsuse K
Nephron; 1997; 77(2):212-8. PubMed ID: 9346389
[TBL] [Abstract][Full Text] [Related]
18. Augmented interleukin-18 production by peripheral blood monocytes in patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Am J Nephrol; 2001; 21(1):20-7. PubMed ID: 11275628
[TBL] [Abstract][Full Text] [Related]
19. Studies of T lymphocyte function and inhibitory factors in minimal change nephrotic syndrome.
Tomizawa S; Suzuki S; Oguri M; Kuroume T
Nephron; 1979; 24(4):179-82. PubMed ID: 315034
[TBL] [Abstract][Full Text] [Related]
20. [In vitro production of a human lymphokine by a specific mitogen in primary glomerular nephropathies].
Laurent J; Heslan JM; Branellec A; Lagrue G
Ann Biol Clin (Paris); 1984; 42(3):207-10. PubMed ID: 6476490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
